GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

This is Prime Therapeutics’ latest research into GLP-1s and the long term impact of taking the medication. In October of last ...